Lyra Therapeutics Adds Laura Edgerly-Pflug as Senior Vice President of Technical Operations

Company strengthens leadership team by adding industry veteran with extensive experience in process development, manufacturing and quality control

Watertown, MA – July 8, 2019 – Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines designed to precisely target ear, nose and throat (ENT) diseases, today announced the addition of Laura M. Edgerly-Pflug as its Senior Vice President of Technical Operations. She brings over 25 years of experience in the biotechnology and pharmaceutical industry, specifically focused on manufacturing and quality control. Ms. Edgerly-Pflug joins Lyra at a pivotal time as the company’s lead drug candidate, LYR-210, enters a Phase 2 clinical trial for the treatment of chronic rhinosinusitis.

“Laura has an impressive track record for leading the manufacturing and commercial scale-up for a range of complex pharmaceutical products. Her expertise is ideally suited to Lyra as we prepare to advance LYR-210 into later-stage clinical trials and plan for future commercialization,” said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics. “Additionally, she brings a wealth of expertise from numerous drug development programs that will help us advance Lyra’s emerging pipeline of ENT medicines we hope will have a meaningful impact for patients. We are delighted to welcome Laura to our management team.”

Ms. Edgerly-Pflug has worked on the development and commercialization of a number of pharmaceuticals and biologics with a wide range of formulations and routes of administration. She has extensive experience in product and process development, scale-up from bench to commercial process, all areas of good manufacturing process compliance, and the development and implementation of quality management systems.  

“I am excited to join Lyra at this transformative time in the company’s evolution, and to work together with this dynamic team as we advance innovative ENT drug candidates and bring new therapies to patients in this growing therapeutic area,” said Ms. Edgerly-Pflug. “I look forward to building and expanding the manufacturing and commercial foundation for Lyra’s lead drug candidate, LYR210, as well as creating the strategy for the company’s pipeline of ENT therapies for a range of diseases.”

Ms. Edgerly-Pflug joins Lyra from her most recent role as Vice President of Technical Operations at Adgero Biopharmaceuticals Holdings, Inc., where she served on the executive leadership team and led the manufacturing, formulation, analytical, and quality control/quality assurance activities for a therapeutic to treat cutaneous cancers. Previously, Ms. Edgerly-Pflug worked at Insmed Incorporated as a Vice President of Technical Operations and Chemistry, Manufacturing and Controls (CMC), with responsibilities for product development, global CMC documentation and submissions, and manufacturing of sterile liposomal products from preclinical development through commercialization. Prior to Insmed, Ms. Edgerly-Pflug held leadership positions at Ovation Pharmaceuticals Inc. (currently Recordati Rare Diseases, Inc.), Biomira Inc. (currently Seattle Genetics, Inc.), and The Liposome Company, Inc. Ms. Edgerly-Pflug began her career in industry as a chemist at Colgate-Palmolive Company. She holds a B.S. in Chemistry from Kean College of New Jersey, attended Rutgers College of Pharmacy, and has authored pharmaceutical patents and publications.

About Lyra Therapeutics Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines designed to precisely target ear, nose and throat (ENT) diseases, offering an alternative to conventional treatments or surgeries. The company’s lead drug candidate, LYR-210, offers a novel approach for the treatment of chronic rhinosinusitis (CRS) by directing anti-inflammatory medicine deep into sinonasal tissues for up to six months of therapy. With proprietary expertise in drug development and materials science, Lyra is applying its transmucosal therapeutic system – comprised of drug administered through a polymeric matrix – with the goal of enabling therapeutic action at the site of inflammation in the sinonasal passages. Lyra Therapeutics is located in Watertown, Massachusetts. For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn.

# # #

Media Contact:
Kathryn Morris
914-204-6412
[email protected]

Investor Contact:
Laurence Watts
619-916-7620
[email protected]